Archived This bill is from the 117th Congress (2021–2022) and is no longer under active consideration.
To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.
House: Referred